Skip to main content
REGN
NASDAQ Life Sciences

新闻发布：赛诺菲和再生元的杜比妥（Dupixent）获得欧盟推荐批准，用于治疗幼儿慢性自发性荨麻疹，适用于症状持续的幼儿

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$768
Mkt Cap
$81.475B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

欧洲药品管理局的人用药物委员会（CHMP）已采纳了积极的意见，推荐批准杜比妥（Dupixent）用于治疗欧盟2至11岁儿童的慢性自发性荨麻疹（CSU）。如果获得批准，这将使杜比妥（Dupixent）成为该特定儿科人群中首个针对不充分控制的CSU的靶向药物。这一发展对再生元来说是一个积极的步骤，因为杜比妥（Dupixent）是公司的关键收入驱动力，如最近的10-K文件中所述。扩大该药的适应症标签到新的适应症和人群有助于其持续增长。投资者应该关注欧洲委员会在未来几个月的最终决定，以及预计2026年4月之前的美国FDA对同一适应症的决定。

在该公告发布时，REGN的交易价格为$768.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$814.7亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article